MX346460B - Uso de catepsina h. - Google Patents

Uso de catepsina h.

Info

Publication number
MX346460B
MX346460B MX2012002627A MX2012002627A MX346460B MX 346460 B MX346460 B MX 346460B MX 2012002627 A MX2012002627 A MX 2012002627A MX 2012002627 A MX2012002627 A MX 2012002627A MX 346460 B MX346460 B MX 346460B
Authority
MX
Mexico
Prior art keywords
cathepsin
pain
aspects
treatment
present
Prior art date
Application number
MX2012002627A
Other languages
English (en)
Other versions
MX2012002627A (es
Inventor
Michaelis Martin
Gebauer Mathias
Ding-Pfennigdorff Danping
M Schulte Anke
Metz-Weidmann Christiane
Original Assignee
Sanofi *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi * filed Critical Sanofi *
Publication of MX2012002627A publication Critical patent/MX2012002627A/es
Publication of MX346460B publication Critical patent/MX346460B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)

Abstract

La presente invención se refiere al uso de Catepsina H. Otros aspectos de la invención se refieren a métodos para seleccionar agentes farmacéuticos, para diagnosticar la susceptibilidad al dolor y para el tratamiento del dolor. Un método para identificar o analizar compuestos que modulan la sensibilidad al dolor neuropático, que comprende: a. poner en contacto una célula, que tiene una expresión detectable de la Catepsina H, con un compuesto de ensayo; y d. determinar si el compuesto de ensayo es capaz de modular la expresión de la Catepsina H presente en la célula.
MX2012002627A 2009-08-31 2010-08-27 Uso de catepsina h. MX346460B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290659A EP2293072A1 (en) 2009-08-31 2009-08-31 Use of cathepsin H
PCT/EP2010/062525 WO2011023786A1 (en) 2009-08-31 2010-08-27 Use of cathepsin h

Publications (2)

Publication Number Publication Date
MX2012002627A MX2012002627A (es) 2012-05-08
MX346460B true MX346460B (es) 2017-03-22

Family

ID=42150608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002627A MX346460B (es) 2009-08-31 2010-08-27 Uso de catepsina h.

Country Status (16)

Country Link
US (1) US20120252878A1 (es)
EP (2) EP2293072A1 (es)
JP (2) JP5980116B2 (es)
KR (1) KR20120073261A (es)
CN (1) CN102713631B (es)
AR (1) AR078002A1 (es)
AU (1) AU2010288468B2 (es)
BR (1) BR112012004450A2 (es)
CA (1) CA2772004A1 (es)
IL (1) IL218326A (es)
MX (1) MX346460B (es)
MY (1) MY179784A (es)
RU (1) RU2574005C2 (es)
SG (2) SG178929A1 (es)
TW (1) TW201113033A (es)
WO (1) WO2011023786A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
CN105969904B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 多发性骨髓瘤生物标志物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
ATE218328T1 (de) 1996-03-25 2002-06-15 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US20040055022A1 (en) * 2000-02-08 2004-03-18 Nick Cheng Compositions and methods for screening therapeutic agents
US20030138803A1 (en) * 2001-07-27 2003-07-24 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20030148314A1 (en) * 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20060241074A1 (en) * 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US20030212003A1 (en) * 2002-02-14 2003-11-13 Hermann Lubbert Cathepsin Y for the development of a medicament for the treatment of pain
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US6897240B2 (en) * 2002-05-08 2005-05-24 The Regents Of The University Of California Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
ES2367311T3 (es) * 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
EP2105742A1 (en) * 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C

Also Published As

Publication number Publication date
MX2012002627A (es) 2012-05-08
US20120252878A1 (en) 2012-10-04
WO2011023786A1 (en) 2011-03-03
SG178929A1 (en) 2012-04-27
KR20120073261A (ko) 2012-07-04
IL218326A (en) 2015-10-29
JP5980116B2 (ja) 2016-08-31
JP2016104013A (ja) 2016-06-09
JP2013502912A (ja) 2013-01-31
EP2293072A1 (en) 2011-03-09
AU2010288468B2 (en) 2015-04-30
CN102713631A (zh) 2012-10-03
MY179784A (en) 2020-11-13
IL218326A0 (en) 2012-04-30
AU2010288468A1 (en) 2012-03-15
EP2473855A1 (en) 2012-07-11
CN102713631B (zh) 2015-12-09
AR078002A1 (es) 2011-10-05
BR112012004450A2 (pt) 2016-11-16
RU2574005C2 (ru) 2016-01-27
TW201113033A (en) 2011-04-16
RU2012112539A (ru) 2013-10-10
SG10201507228XA (en) 2015-10-29
CA2772004A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
MX355543B (es) Macrociclos peptidomiméticos.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
IL222252A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
MX2011007930A (es) Conjugados de insulina cristalina.
EP2179037A4 (en) DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
EP2260109A4 (en) METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR DIAGNOSING, PROGNOSING AND TREATING PROSTATE-RELATED DISORDERS
IN2012DN02737A (es)
WO2010083347A3 (en) Peptidomimetic macrocycles
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
EA201171367A1 (ru) Винилиндазолильные соединения
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
EP2596741A4 (en) ENDOSCOPE AND TREATMENT INSTRUMENT FOR AN ENDOSCOPE
MY158992A (en) Forms of rifaximin and uses thereof
MY155340A (en) Use of cathepsin c
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
EP2609220A4 (en) ASSOCIATION OF RARE RECURRENT GENETIC VARIATIONS WITH HYPERACTIVITY (ADHD) ATTENTION DEFICIT DISORDER AND ASSOCIATED METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF ADHD
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
ZA201101814B (en) Prevention, treatment and diagnosis of p.gingivalis infection
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
HK1203190A1 (en) Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system
MX2009009693A (es) Metodos para activar irs-1 y akt.
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER

Legal Events

Date Code Title Description
FG Grant or registration